Haemonetics (HAE)
Blood-collection platforms and hospital devices for transfusion, surgery, and cardiac procedures.
Something off on this page? Send us feedback.
Sells automated apheresis systems, single-use disposables, donor software, hospital blood-management tools, and interventional devices. Revenue spans Apheresis and MedSurg; plasma collections pair equipment, disposables, and software, while sales remain concentrated among several large operators.
Supplies automated collection systems, single-use disposables, donor-management software, and services through Apheresis, serving plasma centers and blood collectors worldwide. NexSys PCS and its Persona technology tailor source-plasma collections, while MCS and related systems collect and process blood components. The platform links devices with center workflows and software, supporting yield, donor safety, and operating efficiency.
MedSurg combines Blood Management Technologies—TEG hemostasis testing, Cell Saver surgical blood recovery, and SafeTrace Tx and BloodTrack transfusion software—with Interventional Technologies such as VASCADE vascular closure, SavvyWire and OptoWire sensor-guided devices, and ensoETM esophageal cooling. Device approvals vary by country, most consumables are manufactured internally, and Plasma sales remain concentrated among several large collection operators.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 3, 2026 | Raymond James | Reiterate | Rating: —Target: $105 | Target: $125 |
| Aug 21, 2026 | Robert W. Baird | Target | Target: $96 | Target: $119 |
| Aug 19, 2026 | Barrington | Target | Target: $95 | Target: $118 |
| Aug 7, 2026 | Raymond James | Reiterate | Rating: —Target: $90 | Target: $105 |
| Aug 7, 2026 | Robert W. Baird | Target | Target: $67 | Target: $96 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 27, 2026Cash & short-term investments $223.4M · Total debt $1.17B · Total assets $2.37B · Shareholders' equity $837.1M
- Revenue
- $339.4M
- Operating income
- $57.5M
- Net income
- $33.0M
No dividends on record.
| Institutions | 110.47% | 50.26M shares | |
|---|---|---|---|
| 342 holders · as of Jun 30, 2026 | |||
| Insiders | 1.84% | 836.9K shares | |
| 16 holders · as of Jul 28, 2026 | |||
| Adds to | 112.31% | ||
45.50M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 112.31%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 12.99% | 5.91M | as of Jun 30, 2026 |
Neuberger Berman Group LLCInstitution | 9.19% | 4.18M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.60% | 2.55M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 4.98% | 2.27M | as of Jun 30, 2026 |
Ariel Investments, LLCInstitution | 4.53% | 2.06M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 10, 2025 | Mark W. Kroll | director | +1,400 | $70.56 |
- Abbott
Dominant vascular closure and wireless coronary physiology platform
- LivaNova
Global cardiac surgery platform combining HLM, oxygenators, and cell salvage
- Boston Scientific
Major cardiovascular medtech with FFR wires, PFA ablation, and IVUS imaging
- Philips (ADR)
Coronary physiology leader via iFR platform, OmniWire, and IGT imaging systems
- Medtronic
Global medtech leader; competes in cell salvage via active autoLog IQ system
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Haemonetics | $109.02 | +0.27% | $4.94B | 53.3 | 19.8 | 3.7 | +5.6% |
| Abbott | $104.24 | +1.22% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| LivaNova | $78.25 | +0.10% | $4.29B | 23.1 | 17.8 | 2.9 | +10.8% |
| Boston Scientific | $44.76 | +2.37% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Philips (ADR) | $25.01 | +0.42% | $24.34B | 18.7 | 13.0 | 1.2 | −2.8% |
| Medtronic | $90.95 | −0.87% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Median | 22.6 | 15.2 | 3.1 | +10.8% |